Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage

Li Tong, Siddaraju M. Nanjundaiah, Shivaprasad H. Venkatesha, Brian Astry, Hua Yu, Kamal D. Moudgil

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting the synovial joints. The currently available drugs for RA are effective only in a proportion of patients and their prolonged use is associated with severe adverse effects. Thus, new anti-arthritic agents are being sought. We tested Pristimerin, a naturally occurring triterpenoid, for its therapeutic activity against rat adjuvant arthritis. Pristimerin effectively inhibited both arthritic inflammation and cartilage and bone damage in the joints. Pristimerin-treated rats exhibited a reduction in the pro-inflammatory cytokines (IL-6, IL-17, IL-18, and IL-23) and the IL-6/IL-17-associated transcription factors (pSTAT3 and ROR-γt), coupled with an increase in the immunomodulatory cytokine IL-10. Also increased was IFN-γ, which can inhibit IL-17 response. In addition, the Th17/Treg ratio was altered in favor of immune suppression and the RANKL/OPG ratio was skewed towards anti-osteoclastogenesis. This is the first report on testing Pristimerin in arthritis. We suggest further evaluation of Pristimerin in RA patients.

Original languageEnglish (US)
Pages (from-to)220-230
Number of pages11
JournalClinical Immunology
Volume155
Issue number2
DOIs
StatePublished - Dec 1 2014

Keywords

  • Autoimmunity
  • Experimental arthritis
  • Mediators of inflammation
  • Natural products
  • T cell subsets (Th17/Treg)
  • Therapy

Fingerprint Dive into the research topics of 'Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage'. Together they form a unique fingerprint.

Cite this